CN111620782A - 一种盐酸艾司洛尔中间体的制备方法 - Google Patents
一种盐酸艾司洛尔中间体的制备方法 Download PDFInfo
- Publication number
- CN111620782A CN111620782A CN202010416715.0A CN202010416715A CN111620782A CN 111620782 A CN111620782 A CN 111620782A CN 202010416715 A CN202010416715 A CN 202010416715A CN 111620782 A CN111620782 A CN 111620782A
- Authority
- CN
- China
- Prior art keywords
- palladium
- bromophenol
- methyl acrylate
- reaction
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 229960001015 esmolol hydrochloride Drugs 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 21
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 claims abstract description 20
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims abstract description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003054 catalyst Substances 0.000 claims abstract description 19
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 10
- 239000003446 ligand Substances 0.000 claims abstract description 7
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 7
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 claims description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 3
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 claims description 2
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000009776 industrial production Methods 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940126214 compound 3 Drugs 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- NITWSHWHQAQBAW-QPJJXVBHSA-N (E)-4-coumaric acid methyl ester Chemical compound COC(=O)\C=C\C1=CC=C(O)C=C1 NITWSHWHQAQBAW-QPJJXVBHSA-N 0.000 description 6
- NITWSHWHQAQBAW-UHFFFAOYSA-N MpCA Natural products COC(=O)C=CC1=CC=C(O)C=C1 NITWSHWHQAQBAW-UHFFFAOYSA-N 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- QOHGMEYPUKSMST-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)propanoate Chemical compound COC(=O)C(C)C1=CC=C(O)C=C1 QOHGMEYPUKSMST-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000007039 two-step reaction Methods 0.000 description 2
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- FAYGEALAEQKPDI-UHFFFAOYSA-N 4-(2-methoxyethyl)phenol Chemical compound COCCC1=CC=C(O)C=C1 FAYGEALAEQKPDI-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000000332 adrenergic beta-1 receptor antagonist Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- YNUJADNRNHJXDT-UHFFFAOYSA-N palladium;pentane-2,4-dione Chemical compound [Pd].CC(=O)CC(C)=O.CC(=O)CC(C)=O YNUJADNRNHJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
- C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
- C07C2523/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals of the platinum group metals
- C07C2523/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2531/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- C07C2531/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- C07C2531/24—Phosphines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明属于药物有机合成领域,具体涉及一种治疗高血压的药物盐酸艾司洛尔中间体的制备方法。本发明提供的合成路线为:将对溴苯酚在钯催化剂、膦配体存在下与丙烯酸甲酯反应生成生成3‑(4‑羟基苯基)丙烯酸甲酯;将生成3‑(4‑羟基苯基)丙烯酸甲酯在钯碳催化剂存在下氢化,得到目标产物4‑羟基苯丙酸甲酯。该方法反应步骤较短、原料廉价易得、工艺简单,操作方便,不需要特殊的反应条件,因此更适合工业化生产。
Description
技术领域
本发明属于药物有机合成领域,特别涉及一种药物——盐酸艾司洛尔中间体4-羟基苯丙酸甲酯的制备方法。
背景技术
盐酸艾司洛尔是一种快速起效的作用时间短的选择性的β1肾上腺素受体阻滞剂。其主要作用于心肌的β1肾上腺素受体,大剂量时对气管和血管平滑肌的β2肾上腺素受体也有阻滞作用。国内上市的盐酸艾司洛尔制剂为注射液,用于心房颤动、心房扑动时控制心室率,围手术期高血压和窦性心动过速的治疗。
盐酸艾司洛尔化学名为4-(3-异丙氨基-2-羟基丙氧基)苯丙酸甲酯盐酸盐,CAS号81161-17-3,其结构式如1。
专利WO 8201869和文献J Med Chem 1982,25(12),1408说明了制备盐酸艾司洛尔的方法,合成路线如下:化合物3和环氧氯丙烷反应得到化合物2,化合物2与异丙胺反应得到盐酸艾司洛尔。因此,化合物3(4-羟基苯丙酸甲酯)是制备盐酸艾司洛尔的关键中间体。
对于化合物3的合成,文献Tetrahedron Lett,2005,46(36):6145报道了以对羟基苯甲醛为原料,通过Wittig反应和还原反应得到了化合物3。反应仅两步,且产率高,但第一步反应会产生大量的三苯基氧膦难以提纯,而第二步反应用到了化学计量的镁作为还原剂,在工业生产中具有危险性,也不利于降低成本。
文献J.Med.Chem.2005,48,4608公开了一种化合物3的合成方法,同样以对羟基苯甲醛为原料,通过与丙二酸缩合和脱羧,酯化,以及还原得到最终产物,反应均是应用较为成熟的常规反应,但反应中使用的雷尼镍为固态非均相催化剂.催化效率不高.且反应需要三步.不利于操作和降低成本。
文献J.Am.Chem.Soc.2006,128,10,3324公开了一种与前面类似的合成方法,反应的起始原料相同,仅更换了第一步和第三步的催化剂,其中第三步使用了钯碳作为催化剂,提高了反应效率,但反应仍然需要三步,且两步需要加热回流.不利于操作和降低成本。
文献Bioorg.Med.Chem,2018,26(3):703、Bioorg.Med.Chem,2017,25(24):6647和Eur.J.Med.Chem,2018,159:267报道了一种化合物3的合成方法,合成路线同样是经过缩合、还原和酯化,但其将丙二酸替换为了麦氏酸,将还原剂变成了硼氢化钠,反应的第一步将溶剂替换为水,是绿色环保的反应,但反应使用的麦氏酸和化学计量的硼氢化钠,原子经济性不好,同样,反应步骤为3步,不利于操作和降低成本。
另外,文献Org.Lett.2014,16,2248公开了一种新的合成路线,以对溴苯酚为原料,通过碳氢活化反应生成C-C键,再通过将酰胺转化为酯得到化合物3。该反应步骤短,但其起始原料CH3CH2CONHQn不易得,第一步反应温度较高且反应产率低,且原子经济性也较差,另外,该反应使用的碳氢活化应用不成熟,可能不适用于工业生产。
综上,现有合成对4-羟基苯丙酸甲酯的方法还存在反应步骤长,起始原料不易得,不利于降低成本的问题,或者需加热反应,使用化学计量的金属试剂,后处理难,操作要求高,不利于工业化。另外,多数反应还存在原子经济性差等问题。
发明内容
为解决现有技术存在的不足,本发明提供了一种制备盐酸艾司洛尔中间体化合物3的方法,该工艺反应条件步骤较短、原料廉价易得,反应条件温和,原子经济性高,易于工业化生产。
本发明的技术方案是,提供一种盐酸艾司洛尔中间体的制备方法,该方法包括如下工艺步骤:
(a)将对溴苯酚在钯催化剂、膦配体和碱存在下与丙烯酸甲酯反应生成3-(4-羟基苯基)丙烯酸甲酯;
(b)将3-(4-羟基苯基)丙烯酸甲酯在钯碳催化剂存在下氢化,得到4-羟基苯丙酸甲酯。
本发明盐酸艾司洛尔中间体4-羟基苯丙酸甲酯的合成路线可以表示为:
本发明提供了一种全新的4-羟基苯丙酸甲酯制备思路,创新地利用Heck偶联反应和双键氢化反应,即可获得高收率和纯度的目标产物,又具有原子经济性高的优点,制备步骤简短,反应条件温和,原料廉价,适合工业放大生产。
优选地,所述步骤(a)中,钯催化剂使用醋酸钯、氯化钯、三氟乙酸钯、双(三苯基膦)二氯化钯、四(三苯基膦)钯、二(乙酰丙酮)钯中的一种,优选为醋酸钯。
所述的钯催化剂采用催化剂量;优选地,钯催化剂为对溴苯酚摩尔量的0.5%-2%;进一步优选为1%。
优选地,所述步骤(a)中,膦配体使用三苯基膦、三叔丁基膦、三环己基膦、1,2-双(二苯基膦)乙烷中的一种,进一步优选为三苯基膦。
作为优选,膦配体为对溴苯酚摩尔量的2%-4%,进一步优选为3%。
优选地,所述步骤(a)中,碱为三乙胺、4-二甲氨基吡啶、吡啶、碳酸钠、碳酸钾、碳酸氢钠中的一种,进一步优选为吡啶。
优选地,碱为对溴苯酚摩尔量的1.2-2倍;进一步优选为1.5倍。
优选地,所述步骤(a)中,对溴苯酚与丙烯酸甲酯的投料摩尔比为1∶1.1~1.5,进一步优选为1∶1.2。
优选地,步骤(a)中的溶剂是甲苯、四氢呋喃、二氧六环、DMF、乙腈中的任何一种或其混合,优选为二氧六环;对溴苯酚与溶剂投料比为1∶5~30,优选1∶15。
优选地,所述步骤(a)中,反应温度为55~100℃,优选75~85℃。
优选地,所述步骤(a)中,反应时间为5-20h,进一步优选为10h。
步骤(a)反应后,脱除溶剂,去除催化剂后无需纯化直接进行步骤(b)的双键氢化。
优选地,所述步骤(b)中的溶剂是甲醇、乙醇、四氢呋喃、二氧六环、乙酸乙酯中的任何一种或其混合,优选为乙醇;3-(4-羟基苯基)丙烯酸甲酯与溶剂的投料比为1∶15~30,优选1∶25。
优选地,步骤(b)中靶碳的使用量为3-(4-羟基苯基)丙烯酸甲酯的摩尔数的2%。反应的氢气分压为30-50个大气压,优选40个大气压。
优选地,所述步骤(b)中,反应温度为40~70℃,进一步优选为50℃。反应时间为8-20h,优选16h。
氢化反应完成后,通过简单的重结晶,即可高收率、高纯度地获得目的产物。
本工艺路线以对溴苯酚为起始原料,通过两步反应合成中间体3,与原工艺相比,工艺路线较短,未使用危险性高的试剂,原子经济性高,且本工艺反应条件温和,后处理简单,适于工业化生产。虽然两步反应都使用到了价格较高的钯催化剂,但使用量低,且工业化生产钯催化剂可以回收,因此可以降低成本。
具体实施方式
实施例1
步骤(a)3-(4-羟基苯基)丙烯酸甲酯的合成
将17.3g(100mmol)对溴苯酚溶于258g二氧六环,加入0.224g醋酸钯(1mmol),0.787g三苯基膦(3mmol),11.865g吡啶(150mmol),最后加入丙烯酸甲酯10.33g(120mmol),氮气保护下加热至80℃,反应10h后降至室温,减压蒸馏除去溶剂,再加入乙酸乙酯和正己烷的混合溶剂100ml,用水和盐水洗涤干燥后加入活性炭,过滤蒸干溶剂得到油状物18.1g,顺式和反式烯烃产物相加的HPLC纯度为91%,无需纯化直接投入下一步。
步骤(b)4-羟基苯丙酸甲酯(3)的制备
将前一步反应得到的3-(4-羟基苯基)丙烯酸甲酯粗品到加入450g乙醇中,加入2%靶碳(以对溴苯酚为基准),并通入氢气并加压至40个大气压,加热至50℃反应16h,冷至室温后滤去催化剂,水洗后蒸干溶剂。得到的油状物加入二氯甲烷和碳酸钠水溶液,快速搅拌1h后,去除有机相,将水相PH值调至酸性,再用二氯甲烷萃取出目标产物,干燥,过滤,蒸干溶剂。粗品用正己烷/乙酸乙酯重结晶得4-羟基苯丙酸甲酯(3)12.79g,HPLC纯度为99%,以对溴苯酚计算前两步收率为70%。
实施例2
步骤(a)3-(4-羟基苯基)丙烯酸甲酯的合成
将17.3g(100mmol)对溴苯酚溶于258g DMF,加入0.177g氯化钯(1mmol),0.787g三苯基膦(3mmol),15.2g三乙胺(150mmol),最后加入丙烯酸甲酯10.33g(120mmol),氮气保护下加热至70℃,反应15h后降至室温,减压蒸馏除去溶剂,再加入乙酸乙酯和正己烷的混合溶剂100ml,用水和盐水洗涤干燥后加入活性炭,过滤蒸干溶剂得到油状物17.5g,顺式和反式烯烃相加的HPLC纯度为89%,无需纯化直接投入下一步。
步骤(b)4-(2-甲氧基乙基)苯酚(3)的制备
将前一步反应得到的3-(4-羟基苯基)丙烯酸甲酯粗品到加入375g二氧六环中,加入2%靶碳(以对溴苯酚为基准),并通入氢气并加压至30个大气压,加热至50℃反应16h,冷至室温后滤去催化剂,水洗后蒸干溶剂。得到的油状物加入二氯甲烷和碳酸钠水溶液,快速搅拌1h后,去除有机相,将水相PH值调至酸性,再用二氯甲烷萃取出目标产物,干燥,过滤,蒸干溶剂。粗品用正己烷/乙酸乙酯重结晶得4-羟基苯丙酸甲酯(3)11.1g,HPLC纯度为97%,以对溴苯酚计算前两步收率为59.8%。
以上仅为本发明的优选实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作的等效结构或等效流程变换,或直接或间接运用在其他相关的技术领域,均同理包括在本发明的专利保护范围内。
Claims (10)
1.一种制备盐酸艾司洛尔中间体的方法,其特征在于,该方法包括以下步骤:
(a)将对溴苯酚在钯催化剂、膦配体和碱存在下与丙烯酸甲酯反应生成3-(4-羟基苯基)丙烯酸甲酯;
(b)将3-(4-羟基苯基)丙烯酸甲酯在钯碳催化剂存在下氢化,得到4-羟基苯丙酸甲酯。
2.如权利要求1所述的方法,其特征在于,所述步骤(a)中,钯催化剂为醋酸钯、氯化钯、三氟乙酸钯、双(三苯基膦)二氯化钯、四(三苯基膦)钯、二(乙酰丙酮)钯中的一种。
3.如权利要求1或2所述的方法,其特征在于,钯催化剂为对溴苯酚摩尔量的0.5%-2%。
4.如权利要求1所述的方法,其特征在于,所述步骤(a)中,膦配体为三苯基膦、三叔丁基膦、三环己基膦、1,2-双(二苯基膦)乙烷中的一种。
5.如权利要求1或4所述的方法,其特征在于,膦配体为对溴苯酚摩尔量的2%-4%。
6.如权利要求1所述的方法,其特征在于,所述步骤(a)中,碱为三乙胺、4-二甲氨基吡啶、吡啶、碳酸钠、碳酸钾、碳酸氢钠中的一种。
7.如权利要求1或6所述的方法,其特征在于,碱为对溴苯酚摩尔量的1.2-2倍。
8.如权利要求1所述的方法,其特征在于,所述步骤(a)中,对溴苯酚与丙烯酸甲酯的投料摩尔比为1︰1.1~1.5,优选为1:1.2。
9.如权利要求1所述的方法,其特征在于,所述步骤(a)中,反应温度为55~100℃,优选75~85℃。
10.如权利要求1所述的方法,其特征在于,所述步骤(b)中,反应温度为40~70℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010416715.0A CN111620782A (zh) | 2020-05-15 | 2020-05-15 | 一种盐酸艾司洛尔中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010416715.0A CN111620782A (zh) | 2020-05-15 | 2020-05-15 | 一种盐酸艾司洛尔中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111620782A true CN111620782A (zh) | 2020-09-04 |
Family
ID=72256265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010416715.0A Pending CN111620782A (zh) | 2020-05-15 | 2020-05-15 | 一种盐酸艾司洛尔中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111620782A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640834A (zh) * | 2018-03-27 | 2018-10-12 | 湖北广辰药业有限公司 | 艾司洛尔中间体3-(4-羟基苯基)丙酸甲酯的合成工艺 |
CN109553513A (zh) * | 2018-11-28 | 2019-04-02 | 嘉实(湖南)医药科技有限公司 | 一种美托洛尔中间体的制备方法 |
CN110734375A (zh) * | 2018-07-19 | 2020-01-31 | 上海天慈中商药业有限公司 | 一种比拉斯汀中间体的制备方法 |
-
2020
- 2020-05-15 CN CN202010416715.0A patent/CN111620782A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640834A (zh) * | 2018-03-27 | 2018-10-12 | 湖北广辰药业有限公司 | 艾司洛尔中间体3-(4-羟基苯基)丙酸甲酯的合成工艺 |
CN110734375A (zh) * | 2018-07-19 | 2020-01-31 | 上海天慈中商药业有限公司 | 一种比拉斯汀中间体的制备方法 |
CN109553513A (zh) * | 2018-11-28 | 2019-04-02 | 嘉实(湖南)医药科技有限公司 | 一种美托洛尔中间体的制备方法 |
Non-Patent Citations (4)
Title |
---|
PEIWENZHENG ET AL: "Synthesis of efficient and reusable palladium catalyst supported on pH-responsive colloid and its application to Suzuki and Heck reactions in water", 《JOURNAL OF CATALYSIS》 * |
PEIWENZHENG ET AL: "Synthesis of efficient and reusable palladium catalyst supported on pH-responsive colloid and its application to Suzuki and Heck reactions in water", 《JOURNAL OF CATALYSIS》, vol. 250, no. 2, 10 September 2007 (2007-09-10), pages 324 - 330, XP022200530, DOI: 10.1016/j.jcat.2007.06.030 * |
TABATABAEI REZAEI ET AL: "Palladium nanoparticles immobilized on amphiphilic and hyperbranched polymer-functionalized magnetic nanoparticles: An efficient semi-heterogeneous catalyst for Heck reaction", 《APPLIED ORGANOMETALLIC CHEMISTRY》, vol. 31, no. 9, 29 January 2017 (2017-01-29), pages 1 - 10 * |
麻生明著: "《全国高职高专药学类专业规划教材 第二轮 有机化学 第2版》", 中国医药科技出版社, pages: 76 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111187153B (zh) | 一种1,3-环己二酮的制备方法 | |
CN111825546A (zh) | 一种贝派地酸的合成方法 | |
EP1735262A1 (en) | Process for preparing cinnamic acids and alkyl esters thereof | |
CN111620782A (zh) | 一种盐酸艾司洛尔中间体的制备方法 | |
EP1213279B1 (en) | Venlafaxine production process | |
CN114702425B (zh) | (s)-2-氨基-(s)-3-[吡咯烷酮-2’]丙氨酸衍生物及中间体的制备方法 | |
CN112645866B (zh) | 1-苄基-4-甲基-5-烷氧基-1,2,3,6-四氢吡啶衍生物的合成及应用 | |
CN111807968B (zh) | 一种2-(1-环己烯基)乙胺的合成方法 | |
KR20010074521A (ko) | 3-하이드록시프로피오니트릴의 제조방법 | |
EP1732899B1 (en) | Process for preparing cyclohexanediacetic acid monoamide | |
JP3982991B2 (ja) | 光学活性1−(トリフルオロメチルモノ置換フェニル)エチルアミンの製造方法 | |
CN113387874B (zh) | 6,6-二烷基哌啶-2-羧酸化合物的合成方法 | |
CN116730832B (zh) | 一种2-丙基己酸的制备方法 | |
CN116178210B (zh) | 一种香茅腈衍生物的制备方法 | |
CN110894184B (zh) | 一种基于绿色环保的替格瑞洛中间体的制备方法 | |
CN113896647B (zh) | 一种叔酰胺的合成方法 | |
CN113372369A (zh) | 一种2-甲酰基-4-氟苯硼酸频哪醇酯的制备方法 | |
JP3864657B2 (ja) | 芳香族アクリロニトリルの製造法 | |
CN113121341A (zh) | 一种合成2,6-二乙基-4-甲基苯乙酸酯的方法 | |
CN117402085A (zh) | 一种合成d-n-boc-联苯丙胺醇的新方法 | |
JPS60132940A (ja) | α‐置換アクリル酸アミドの製法 | |
CN116606250A (zh) | 一种孟鲁司特钠关键中间体的制备方法 | |
CN117402118A (zh) | 一种瑞舒伐他汀钙中间体的制备方法 | |
CN112811991A (zh) | 一种对甲氧基苯乙烯的合成方法 | |
CN116396331A (zh) | 一种手性2,5-二苯基磷酸的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200904 |